Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04782388 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants
A Phase 1 study of Healthy Study Participants, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04782388 is a Phase 1 study of Healthy Study Participants that has completed, run by UCB Biopharma SRL. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04782388, a Phase 1 study of Healthy Study Participants, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of Staccato alprazolam in healthy Japanese, Chinese, and Caucasian participants.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Alprazolam
Study Locations (1)
California
- Up0101 101 - Anaheim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2021-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04782388
The ClinicalTrials.gov registry entry for NCT04782388 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Study Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04782388 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04782388 about?
NCT04782388 is a clinical study titled "Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants". The purpose of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of Staccato alprazolam in healthy Japanese, Chinese, and Caucasian participants.
What is the current status of trial NCT04782388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-03-04. Estimated completion is 2021-04-26.
What conditions does trial NCT04782388 study?
This clinical trial studies the following conditions: Healthy Study Participants.
What interventions are being tested in trial NCT04782388?
The interventions under investigation include: Placebo (OTHER), Alprazolam (DRUG).
Who is sponsoring clinical trial NCT04782388?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04782388 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Study Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
RECRUITING · Phase 1
-
A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.